important to determine the appropriate stent diameter and length. The femoral sheath was then converted to a No. 8 French sheath to accommodate the angioplasty balloon and stent. A No. 8 French 90-cm guiding catheter (Vista Brite Tip; Cordis Endovascular, Johnson and Johnson Corp.) was positioned in the CCA. Based on their weight, patients then received boluses of heparin and were maintained on a continuous drip to keep the activated clotting time at two times the baseline value.
With the aid of roadmap guidance, a 0.35 to 0.38-in Terumo guidewire (Boston Scientific, Fremont, CA) was passed through the stenosis. The Savvy angioplasty balloon catheter system (Cordis Endovascular, Johnson and Johnson Corp.) was then passed over the wire, across the stenosis, and the balloon was inflated up to 8 to 10 atm (Fig. 1b) . The pressure of balloon inflation was dependent on tactile and radiographic assessment. The number of balloon inflations was determined based on pre-and postdilation angiograms. A follow-up angiogram was obtained after each inflation. If results of the angiogram were not satisfactory, repeated angioplasty was performed (Fig.  1c) . Once angioplasty was deemed adequate on the preliminary angiogram, a nitinol transhepatic biliary system stent and catheter system was passed across the diseased area under roadmap guidance.
The types of stents used in our series included 22 SMART (Cordis Endovascular) and one ACCULINK (Guidant Corp., Santa Clara, CA) device. The size of stents used in our series varied in length from 20 to 40 mm and in diameter from 5 to 8 mm. After the device was positioned, a follow-up angiogram was obtained to ensure that the postdelivery dilation of the stent was adequate (Fig. 1d) . If not, balloon dilation was performed after delivery of the stent. Once treatment was completed, a lowmagnification angiogram was obtained to view the carotid bifurcation and intracranial vessels to evaluate for thromboembolic events. Postoperatively, patients were maintained on a continuous heparin infusion for 24 to 48 hours to a goal activated clotting time of 2 to 2.5 times baseline. Patients were discharged on a maintenance dose of aspirin and clopidogrel.
RESULTS
Twenty-three vessels in 22 patients were treated using CA angioplasty and stent placement for recurrent stenosis after CEA. The mean patient age was 71 years. The mean period between CEA and CA angioplasty and stent placement was 28 months. All patients had high-grade stenosis (Ͼ 80%) on angiography. Twenty-two patients presented with transient ischemic attacks or amaurosis fugax, whereas one was asymptomatic. There were no neurological or cardiac complications in this series in the perioperative period. In one patient a groin/retroperitoneal hematoma developed, which required blood transfusion and delayed hospital discharge. During a mean clinical follow-up period of 36 months no further ischemic events occurred in this series of patients. Follow-up duplex ultrasonography studies performed every 6 months after CA angioplasty and stent placement were available on 20 vessels in 19 patients and demonstrated one case of recurrent stenosis (4%) 14 months after CA angioplasty and stent placement, which was treated with angioplasty alone.
DISCUSSION
The incidence of recurrent stenosis after CEA ranges from 2 to 50%, depending on the routine use of follow-up imaging studies, follow-up duration, and methods/criteria for defining restenosis. Two distinct pathophysiological processes are responsible for recurrent CA stenosis. Stoney and String 11 found that early restenosis (Ͻ 24 months postoperatively) was due to fibrous myointimal hyperplasia, whereas late restenosis (Ն 24 months) was due to progressive atherosclerotic disease of the vessel. Surgical management of recurrent CA stenosis is technically more challenging, leading to increased complication rates compared with the initial endarterectomy. Meyer, et al., 7 described an 11% major morbidity/mortality rate with repeated CEA due to the difficulty of dissecting scarred planes between the recurrent atheroma and underlying media and due to the friable nature of a recurrent plaque, increasing the risk of emboli. The durability of reoperation for recurrent disease is also an issue; delayed failure, including ischemic events, is as high as 20%. 3 The need for a safer and more durable treatment prompted the application of endovascular techniques to manage recurrent CA disease. Tievsky, et al., 13 published one of the first reports of balloon angioplasty for the management of postoperative restenosis following CEA in 1983. They described successful treatment of a CCA plaque attributed to clamp injury during a second CEA in a patient with severe coronary disease status after cardiac bypass with ventricular arrhythmias. In another early series, investigators described successful revascularization in four of five vessels treated with balloon angioplasty alone without neurological complications. 12 The initial experience with CA angioplasty and stent placement for recurrent stenosis demonstrated a stroke rate of 4% and no evidence of restenosis on 6-month postprocedure angiography. 14 The addition of stents to angioplasty for the endovascular management of recurrent CA stenosis reduces the risk of emboli from a friable vessel wall and provides a more durable endoluminal frame. Lanzino, et al., 5 evaluated outcomes of angioplasty alone and CA angioplasty and stent placement, demonstrating a higher recurrence rate in the group treated with angioplasty alone, with no neurological complications in 16 patients over a mean follow-up duration of 27 months. In a number of single-institution studies, the CA angioplasty and stent placement procedure was compared with repeated CEA for recurrent CA disease, and angioplasty and stent placement was found to be equivalent or better in terms of neurological outcome and restenosis rates between the two treatment groups. 1, 4, 10 We successfully treated 23 vessels in 22 patients with no neurological complications and one case of restenosis over a mean follow-up duration of 36 months. There was one groin complication (4.5%) in this series, which is slightly higher than our overall experience with CA angioplasty and stent placement, for which the incidence is 2%. This compares favorably with the 4 to 10% risk of wound hematoma or infection and cranial nerve injury associated with repeated endarterectomy. 3, 6 Although no thromboembolic complications occurred in our series, endovascular management of CA stenosis after CEA allows for recognition and treatment with intraarterial mechanical devices and/or thrombolytic agents during the procedure. The role of distal protection devices for CA angioplasty and stent placement for recurrent CA disease has not been well examined, and in our series there were no neurological complications when distal protection was not used.
It is important to note that there were no cardiac events, despite severe coronary artery disease in most patients in our series. For patients at high risk of cardiac or other medical complications during repeated CEA, CA angioplasty and stent placement requires less anesthesia time and can be performed with patients in a state of conscious sedation, thus reducing complications attributed to general anesthesia. The main issue in comparing repeated surgery with CA angioplasty and stent placement for recurrent CA stenosis is durability. The introduction of drug-eluting stents has revolutionized the management of coronary artery disease by significantly reducing the incidence of restenosis. 8 The application of these devices to CA angioplasty and stent placement will likely improve long-term outcomes, providing an even greater advantage for endovascular treatment of recurrent CA stenosis. There is an ongoing need to compare CA angioplasty and stent placement to CEA in a prospective randomized fashion. Many ongoing trials should provide a larger patient experience and more definitive outcomes on which management decisions for CA disease will be based.
CONCLUSIONS
Our experience with CA angioplasty and stent placement in a limited number of patients confirms the safety and durability of endovascular management of recurrent CA stenosis. The application of bioactive and drug-eluting stents in the future should further improve the durability of endovascular management of recurrent stenosis after CEA.
